Sangamo Announces R&D Organization Changes
Going forward, research and development will each be managed as separate functions. A search for a Head of Development is underway.
“The changes we are announcing today are designed to increase the speed and efficiency of the clinical translation of our ground-breaking science into genomic medicines,” said
Sangamo today also announced the departure of
Sangamo Forward Looking Statements
This press release contains forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to Sangamo’s ability to discover, develop, obtain regulatory approvals for and commercialize therapies to treat disease, Sangamo’s anticipated research, development and technological capabilities and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Sangamo’s actual results may differ materially and adversely from those expressed. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the evolving COVID-19 pandemic and its impact on the global business environment, healthcare systems and the business and operations of Sangamo and its collaborators; the research and development process; the uncertain timing and unpredictable results of clinical trials, including whether final clinical trial data will validate the safety and efficacy of product candidates; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; the manufacturing of products and product candidates; the commercialization of approved products; the potential for technological developments that obviate technologies used by Sangamo and its collaborators; the potential for collaborators to breach or terminate their collaboration agreement with Sangamo; and the potential for Sangamo for fail to realize its expected benefits of its collaborations. There can be no assurance that Sangamo and its collaborators will be able to develop and obtain the necessary regulatory approvals for commercially viable products. These risks and uncertainties are described more fully in Sangamo's filings with the
Investor Relations – Global
Media Inquiries – Global